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A B S T R A C T 
Pemphigus vulgaris is an autoimmune bullous dermatosis that affects between 0,1 and 0,5%000 of the popula­
tion. The prognosis of the disease is determined by the severity of the side effects of corticosteroid therapy and 
their compensation. The present study covered 52 patients with pemphigus vulgaris treated in the Clinic of 
Dermatology and Venereology, Prof. P. Stoyanov Medical University of Varna, during a 10-year period 
(1990-2000). There were 20 males aged between 28 and 86 years and 32 females aged between 17 and 77 years. 
The adverse effects of the corticosteroids in the patients with pemphigus vulgaris and their influence on the 
course of the disease were described. The combination with a cytostatic drug (cyclophosphamide or imuran) 
proved to be effective in reducing the total course and maintenance dosage of the corticostteroids in these pa­
tients. 
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Pemphigus vulgaris has been described by Wichmann in 
1791. It is an autoimmune blistering disease presenting 
with acantholysis and bullous-erosive cutaneous and 
mucosal skin lesions (1,7). The natural course of the disease 
is progressive and leads to fatal outcome until the end of the 
first year in 75% of the patients. There is major progress in 
the understanding of its pathophysiology and in the devel­
opment of new diagnostic techniques and therapeutic ap­
proaches (6). Incorporation of corticosteroids (CS) into the 
therapy since 1950 onwards sharply reduces the death rate 
down to approximately 30% (10). Recently, there is a con­
tinuous trend towards a lower mortality rate and nowadays 
it is below 10%. Although CS use remains the cornerstone 
of effective therapeutic regimens for pemphigus vulgaris, 
such a prolonged administration leads to unavoidable side 
effects determining the prognosis (2,8). Systemic 
immunosuppression makes use of CS such as azathioprine, 
dapsone, methotrexate, cyclophosphamide and gold as ad­
juvants or alternatives (9). Immunomodulation is widely 
applied, too (2,5,6). High-dose intravenous immunoglobu­
lin is effective in 81% of the patients with pemphigus 
vulgaris which are more likely to respond to adjunctive 
therapy than to monotherapy (91 % and 56% response rate, 
respectively) (4). Pulse intravenous cyclophosphamide is 
particularly efficacious and low toxic (3). Both 
cyclophosphamide and methylprednisolone "pulse ther-
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ару" are reserved for cases unresponsive to high doses of 
oral CS (8). 
The purposes of the present study are to follow-up the ther­
apeutic results from the treatment of the patients with 
pemphigus vulgaris, the adverse effects of the therapy with 
CS alone and in combination with cytostatic drugs and to 
suggest a model of therapeutic behaviour for minimization 
these unwanted effects. 
M A T E R I A L AND M E T H O D S 
The study covered a total of 52 patients with pemphigus 
vulgaris treated in the Clinic of Dermatology and 
Venereology, Prof. P. Stoyanov Medical University of 
Varna, during a 10-year period (January 1, 1990 - January 
1, 2000). They represented 0,95% of 5447 patients hospi­
talized in the Clinic of Dermatology and Venereology dur­
ing this period. Their total hospital sojourn amounted to 
4050 days (4,12% of the days of all the patients). There 
were 20 males (38,5%) aged between 28 and 86 years and 
32 females (61,5%) aged between 17 and 77 years. Pa­
tients' records were analyzed by means of a special file card 
taking into consideration the following items: 
i) from the anamnesis and status: gender, age, primary lo­
calization of lesions, accompanying diseases, duration of 
remissions, number of hospital days; 
ii) from the paraclinical parameters: ESR, leukocyte count, 
blood sugar, urea, histologic examinations of skin and 
mucosal membranes, 
iii) from the treatment: kind and initial dosage of CS, total 
weekly and average daily dosage for achieving the remis­
sion, and 
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I complications from CS therapy and cause for death. 
R E S U L T S AND D I S C U S S I O N 
I the patients were treated with CS such as hydrocorti-
те, prednisolone, methylprednisolone (MP), and dexa-
rthasone. The mean initial dose was equivalent to 57,5 
I of MP/24 hours. The mean daily dose of CS varied 
m 54,3 lmg MP/24 hours in the first week down to 
,03mg MP/24 hours in the fourth month. The average 
lintenance dose was of ll,13mg MP/24 hours. A 
ostatic drug such as cyclophosphamide or imuran was 
led to the therapy in one half of the patients admitted to 
ipital. The mean daily dosage for achieving the remis-
n was of 186,5mg/24 hours for cyclophosphamide and 
3,5mg/24 hours for imuran. The hospital stay of the pa-
its treated with CS alone was on the average 30,2 hospi-
days long while that of the patients with accompanying 
ostatic therapy was 48,6 hospital days long. The remis-
n occurred between the third and the eight week with 
st patients. It is, therefore, accepted that the duration of 
hospital treatment coincides with the time required for 
lieving the remission. 
mplications due to CS therapy were observed in 44 pa-
its (85% of the acses) treated longer than one year. Arte-
hypertension was most common - in 17 patients 
,6%). Next came obesity and fades limata - in 13 pa-
its (25%), steroid diabetes and disturbed glucose toler-
e as well as bacterial infections such as abscessus. pneu-
nia and sepsis - in 7 patients (13,4%) each, proximal 
opathy - in 6 patients (11,5%), severe osteoporosis with 
lological fractures - in 3 patients (5,7%), thromboses 
embolisms - in 2 patients (3,8%). The sum was higher 
l 52 as there were more complications in one and the 
le patient. Six patients (11,5% of the cases) died during a 
year period from the onset of the disease. The death re­
ed from a progressive cardiovascular and respiratory 
ire in 4 patients, from pulmonary thromboembolism 
from cerebral stroke - in one patient each, 
side effect of CS required cessation of the treatment as it 
/ithout any alternative at all. The arterial hypertension 
compensated by antihypertensive dings in 32,6% of 
patients. The course of the bacterial infections was pro-
ted and with relapses in 13,4% of the cases. As a rule, 
• were managed with antibiotic combinations rather 
I by monotherapy alone. Increasing overweight and re-
ibution of fatty deposits in 25% of the patients tended 
ormalization during the periods of longer remissions, 
vever, the intake of Ca 2* preparations and the periodic 
relic therapy failed to prevent the progressive osteopo-
; having provoked pathological bone fractures and a 
:imal neuropathy. The adverse effects of CS in the pa-
s with pemphigus vulgaris are in a direct dependence 
le sum dosage and duration of treatment. One way to 
ce this dosage is to combine the immunosuppressive 
:t of CS with that of the cytostatics like in one half of 
Datients. The immunosuppressive effect of imuran in a 
dose of 3-4mg/kg b. w. occurred after 3-4 weeks and coin­
cided with the reduction of CS dosage after achieving the 
morbistasis. Its relatively better tolerability has made it ap­
propriate for a long-lasting maintenance therapy for 12-24 
months. Cyclophosphamide was effective in a dosage of 
2-3 mg/kg b. w. It was used in patients unresponsive to CS 
only because of its higher toxicity. 
C O N C L U S I O N ^ 
With a view to reduction of the total course and mainte­
nance dosage of CS it seems reasonable to combine these 
drugs with cytostatic ones even in the slight forms of 
pemphigus vulgaris. The different therapeutic protocols 
should obligatorily be accompanied with a strict control of 
the arterial blood pressure and blood sugar. Additionally, 
use of prophylactic gastroscopy and bone densitometry is 
strongly recommended, particularly in menopausal 
women. 
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